Synonyms
Definition
Classical Hodgkin lymphoma is a clonal lymphoproliferative disorder of B-cell origin (Kuppers 2009) composed by a relatively small number of malignant cells occurring in a reactive benign inflammatory background.
Clinical Features
Epidemiology
CHL accounts for approximately 0.6% of all new cancer cases and 15–30% of all malignant lymphomas (Nakatsuka and Aozasa 2006). The incidence of CHL is higher in industrialized nations than in developing countries. CHL shows a bimodal age of distribution, with a peak in young adult (between 15 and 35 years old) and a second peak in late life after 55 years old. CHL represents the most common subtype of malignant lymphoma in young people in the Western world. CHL is rare in children and exceptional before 3 years old. Male/female ratio is 1.5:1 in children and older adults and 1:1 in younger adult patients. The disease is more frequent in white than hispanic or black people. The incidence is also...
This is a preview of subscription content, log in via an institution.
References and Further Reading
Ansell, S. M., Lesokhin, A. M., Borrello, I., et al. (2015). PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. The New England Journal of Medicine, 372, 311–319.
Behringer, K., Goergen, H., Muller, H., et al. (2016). Cancer-related fatigue in patients with and survivors of Hodgkin lymphoma: The impact on treatment outcome and social reintegration. Journal of Clinical Oncology, 34, 4329–4337.
Biggar, R. J., Jaffe, E. S., Goedert, J. J., et al. (2006). Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood, 108, 3786–3791.
Casasnovas, R. O., Bouabdallah, R., Brice, P., et al. (2019). PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): A randomised, multicentre, non-inferiority, phase 3 study. The Lancet Oncology, 20, 202–215.
Copie-Bergman, C., Gaulard, P., Maouche-Chretien, L., et al. (1999). The MAL gene is expressed in primary mediastinal large B-cell lymphoma. Blood, 94, 3567–3575.
Cozen, W., Li, D., Best, T., et al. (2012). A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32. Blood, 119, 469–475.
Doring, C., Hansmann, M. L., Agostinelli, C., et al. (2014). A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma. Modern Pathology, 27, 1345–1354.
Flavell, K. J., & Murray, P. G. (2000). Hodgkin’s disease and the Epstein-Barr virus. Molecular Pathology, 53, 262–269.
Garnier, J. L., Lebranchu, Y., Dantal, J., et al. (1996). Hodgkin’s disease after transplantation. Transplantation, 61, 71–76.
Gomez-Gelvez, J. C., & Smith, L. B. (2015). Reed-Sternberg-like cells in non-Hodgkin lymphomas. Archives of Pathology & Laboratory Medicine, 139, 1205–1210.
Harris, N. L. (1999). Hodgkin’s disease: Classification and differential diagnosis. Modern Pathology, 12, 159–175.
Isaacson, P. G., Schmid, C., Pan, L., et al. (1992). Epstein-Barr virus latent membrane protein expression by Hodgkin and Reed-Sternberg-like cells in acute infectious mononucleosis. The Journal of Pathology, 167, 267–271.
Jardin, F., Pujals, A., Pelletier, L., et al. (2016). Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. American Journal of Hematology, 91, 923–930.
Kapatai, G., & Murray, P. (2007). Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma. Journal of Clinical Pathology, 60, 1342–1349.
Kuppers, R. (2009). Molecular biology of Hodgkin lymphoma. Hematology. American Society of Hematology. Education Program, 2009, 491–496.
Kuppers, R. (2012). New insights in the biology of Hodgkin lymphoma. Hematology. American Society of Hematology. Education Program, 2012, 328–334.
Liang, W. S., Vergilio, J. A., Salhia, B., et al. (2019). Comprehensive genomic profiling of Hodgkin lymphoma reveals recurrently mutated genes and increased mutation burden. The Oncologist, 24, 219–228.
Liu, Y., Abdul Razak, F. R., Terpstra, M., et al. (2014). The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing. Leukemia, 28, 2248–2251.
Mack, T. M., Cozen, W., Shibata, D. K., et al. (1995). Concordance for Hodgkin’s disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. The New England Journal of Medicine, 332, 413–418.
Nakatsuka, S., & Aozasa, K. (2006). Epidemiology and pathologic features of Hodgkin lymphoma. International Journal of Hematology, 83, 391–397.
Neagu, M., Albulescu, R., & Tanase, C. (2015). Signaling molecule c-Met is a biomarker for favorable prognostic in Hodgkin lymphoma. Biomarkers in Medicine, 6, 197–200.
Nicolae, A., Pittaluga, S., Venkataraman, G., et al. (2013). Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin/Reed-Sternberg cells of B-cell lineage: Both EBV-positive and EBV-negative variants exist. The American Journal of Surgical Pathology, 37, 816–826.
O’Malley, D. P., Fedoriw, Y., & Weiss, L. M. (2016). Distinguishing classical hodgkin lymphoma, gray zone lymphoma, and large B-cell lymphoma: A proposed scoring system. Applied Immunohistochemistry & Molecular Morphology, 24, 535–540.
Raemaekers, J. M. (2015). Early FDG-PET adapted treatment improves the outcome of early FDG-PET positive patients with stage I/II Hodgkin lymphoma (HL): Final results of the randomized Intergroup EORTC/LYSA/FIL H10 trial. 13th International Conference on Malignant Lymphoma (ICML) Lugano Switserlzand.
Raemaekers, J. M., Andre, M. P., Federico, M., et al. (2014). Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. Journal of Clinical Oncology, 32, 1188–1194.
Rengstl, B., Newrzela, S., Heinrich, T., et al. (2013). Incomplete cytokinesis and re-fusion of small mononucleated Hodgkin cells lead to giant multinucleated Reed-Sternberg cells. Proceedings of the National Academy of Sciences of the United States of America, 110, 20729–20734.
Sarkozy, C., Molina, T., Ghesquieres, H., et al. (2017). Mediastinal gray zone lymphoma: Clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. Haematologica, 102, 150–159.
Sarkozy, C., Copie-Bergman, C., Damotte, D., et al. (2019). Gray-zone lymphoma between cHL and large B-cell lymphoma: A histopathologic series from the LYSA. The American Journal of Surgical Pathology, 43, 341–351.
Savage, K. J., & Steidl, C. (2016). Immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma: How they work and when to use them. Expert Review of Hematology, 9, 1007–1009.
Savage, K. J., Monti, S., Kutok, J. L., et al. (2003). The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood, 102, 3871–3879.
Savage, K. J., Mottok, A., & Fanale, M. (2016). Nodular lymphocyte-predominant Hodgkin lymphoma. Seminars in Hematology, 53, 190–202.
Son, E. M., & Huh, J. (2014). Reed-Sternberg-like cells in follicular lymphoma. Blood Research, 49, 147.
Steidl, C., Telenius, A., Shah, S. P., et al. (2010). Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood, 116, 418–427.
Swerdlow, S. H. (2008). WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer.
Swerdlow, S.H. (2016). WHO classification of Tumours of Haematopoietic and lymphoid tissues. Lyon.
Tousseyn, T., & De Wolf-Peeters, C. (2011). T cell/histiocyte-rich large B-cell lymphoma: An update on its biology and classification. Virchows Archiv, 459, 557–563.
Traverse-Glehen, A., Davi, F., Ben Simon, E., et al. (2005a). Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection. Haematologica, 90, 470–478.
Traverse-Glehen, A., Pittaluga, S., Gaulard, P., et al. (2005b). Mediastinal gray zone lymphoma: The missing link between classic Hodgkin’s lymphoma and mediastinal large B-cell lymphoma. The American Journal of Surgical Pathology, 29, 1411–1421.
Tudor, C. S., Bruns, H., Daniel, C., et al. (2014). Macrophages and dendritic cells as actors in the immune reaction of classical Hodgkin lymphoma. PLoS One, 9, e114345.
Viviani, S., Zinzani, P. L., Rambaldi, A., et al. (2011). ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. The New England Journal of Medicine, 365, 203–212.
von Tresckow, B., Plutschow, A., Fuchs, M., et al. (2012). Dose-intensification in early unfavorable Hodgkin’s lymphoma: Final analysis of the German Hodgkin Study Group HD14 trial. Journal of Clinical Oncology, 30, 907–913.
Xiao, W., Chen, W. W., Sorbara, L., et al. (2016). Hodgkin lymphoma variant of Richter transformation: Morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion. Human Pathology, 55, 108–116.
Younes, A., Gopal, A. K., Smith, S. E., et al. (2012). Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. Journal of Clinical Oncology, 30, 2183–2189.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this entry
Cite this entry
Traverse-Glehen, A., Fontaine, J., Ghesquières, H. (2019). Hodgkin Lymphoma, Classical. In: van Krieken, J. (eds) Encyclopedia of Pathology. Encyclopedia of Pathology. Springer, Cham. https://doi.org/10.1007/978-3-319-28845-1_3888-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-28845-1_3888-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-28845-1
Online ISBN: 978-3-319-28845-1
eBook Packages: Springer Reference MedicineReference Module Medicine